Berends D, Mulder A H, van Houwelingen G, de Both N J
Department of Pathology, Medical Faculty, Erasmus University, Rotterdam, The Netherlands.
Int J Cancer. 1988 Jul 15;42(1):42-7. doi: 10.1002/ijc.2910420109.
A syngeneic monoclonal antibody (MAb) (IC5F5) was successfully used in the immunotherapy of Rauscher-virus-induced myeloid leukemic RMB-I cells. It is directed to a virus-encoded, but aberrantly processed protein, which is expressed on the cell membrane. When applied in vivo, it binds only to RMB-I tumor cells. BALB/c mice were inoculated i.p. or i.v. with 10(7) RMB-I cells and died within 2-3 weeks due to increasing tumor load. Mice inoculated i.p. were completely cured by daily injections of ascites containing IC5F5. Disseminated tumor cells in liver and hemopoietic organs were observed after i.v. inoculation. Daily treatment with MAbs resulted in survival beyond 90 days. No antigenic modulation was observed when tumor tissue was analyzed 2-10 days after treatment. Treatment was successful even when therapy was postponed until day 5 following inoculation of tumor cells. When the number of ascites injections was reduced, survival was identical to that observed among repeatedly treated mice. Ten- and 100-fold dilution of ascites fluid diminished the number of survivors, but still resulted in a median survival time of 38 and 20 days, respectively, as compared to 14 days for untreated mice.
一种同基因单克隆抗体（MAb）（IC5F5）已成功用于劳舍尔病毒诱导的髓性白血病RMB-I细胞的免疫治疗。它针对一种病毒编码但加工异常的蛋白质，该蛋白质在细胞膜上表达。体内应用时，它仅与RMB-I肿瘤细胞结合。将10⁷个RMB-I细胞经腹腔或静脉接种到BALB/c小鼠体内，小鼠因肿瘤负荷增加在2至3周内死亡。经腹腔接种的小鼠通过每日注射含IC5F5的腹水而完全治愈。静脉接种后，在肝脏和造血器官中观察到播散的肿瘤细胞。每日用单克隆抗体治疗可使小鼠存活超过90天。治疗后2至10天分析肿瘤组织时未观察到抗原调变。即使将治疗推迟至接种肿瘤细胞后的第5天，治疗仍取得成功。当腹水注射次数减少时，存活率与反复治疗的小鼠相同。腹水液10倍和100倍稀释会减少存活小鼠数量，但与未治疗小鼠的14天相比，中位存活时间仍分别为38天和20天。
